Maria Teresa Escobedo

US Patent:

7060271, Jun 13, 2006

Filed:

Jan 7, 1998

Appl. No.:

09/003810

Inventors:

Vanitha Ramakrishnan - Belmont CA, US
Maria Amelia Escobedo - San Francisco CA, US
Larry J. Fretto - Belmont CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241431, 4241301, 4241331, 4241411, 4241521, 4241721, 5303871, 5303873, 5303881, 5303882, 53038822

Abstract:

The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

US Patent:

20020009443, Jan 24, 2002

Filed:

Oct 15, 1999

Appl. No.:

09/419076

Inventors:

VANITHA RAMAKRISHMAN - BELMONT CA, US
MARIA AMELIA ESCOBEDO - SAN FRANCISCO CA, US
LARRY J. FRETTO - BELMONT CA, US

International Classification:

A61K039/395
C07K016/00
A61K039/42
A61K039/40
C12P021/08

US Classification:

424/133100, 424/141100, 424/152100, 530/388220, 530/387300

Abstract:

The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

US Patent:

20030228307, Dec 11, 2003

Filed:

May 16, 2003

Appl. No.:

10/439168

Inventors:

Vanitha Ramakrishnan - Belmont CA, US
Maria Escobedo - San Francisco CA, US
Larry Fretto - Belmont CA, US

International Classification:

A61K039/395
C07K016/44
C07K016/28

US Classification:

424/143100, 530/388220, 530/387300

Abstract:

The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

US Patent:

58173102, Oct 6, 1998

Filed:

Jun 10, 1994

Appl. No.:

8/258283

Inventors:

Vanitha Ramakrishnan - Belmont CA
Maria Amelia Escobedo - San Francisco CA
Larry J. Fretto - Belmont CA
Nathalie Lokker - San Francisco CA

Assignee:

COR Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 39395
C07K 1628
C07H 2102
G01N 3353

US Classification:

4241431

Abstract:

The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.